Off Patent
July 2027

Halaven

eribulin mesylate

Eisai Inc

Solution (intravenous) · NDA 201532

Last listed protection ends
July 8, 2027

The FDA lists 1 patent and 2 exclusivities for Halaven, and this is the day the last one ends. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Other exclusivity
    FDA code M-280
  2. Ended
    Pediatric exclusivity
    FDA code PED
  3. Patent RE46965
    Claims the drug product
  4. Patent RE46965
    Pediatric extension: six more months